Mack Savage, MD, FACS

Mack Savage, MD, FACS, is a board-certified ophthalmologist and a Fellow of the American College of Surgeons, serving as the Physician and Owner of Savage Retina LLC in Sedalia, Missouri. Dr. Savage is committed to providing advanced, patient-centered care in retinal diseases, offering both medical and surgical solutions for complex retinal conditions. He emphasizes individualized treatment plans, combining cutting-edge techniques with compassionate care to preserve and enhance patients’ vision and quality of life.

Dr. Savage completed his ophthalmology residency at the University of Missouri in Columbia, where he developed a comprehensive foundation in all aspects of eye care. He subsequently completed a highly specialized two-year surgical retina fellowship at the Kresge Eye Institute in Detroit, Michigan, gaining extensive experience in advanced retinal surgery and complex ocular disease management. He also served as a Resident Physician at The University of Iowa Health Care, further honing his clinical and surgical expertise. His rigorous training equips him to handle a wide spectrum of retinal disorders with precision, skill, and a commitment to excellence.

Prior to founding Savage Retina LLC, Dr. Savage practiced at Retina Associates KC, where he developed a reputation for excellence in patient care and surgical outcomes. Board-certified by the American Board of Ophthalmology, he integrates his clinical expertise, surgical proficiency, and dedication to building meaningful relationships with patients to deliver superior ophthalmic care. Beyond his clinical practice, Dr. Savage is actively engaged in ongoing research and professional education, contributing to the advancement of retinal medicine and surgical techniques. His commitment to innovation, continuous learning, and patient-centered care distinguishes him as a leader in the field of ophthalmology.

• University of Iowa Roy J. and Lucille A. Carver College of Medicine - MD

• American Board of Ophthalmology

• American Academy of Opthalmology
• American Society of Retina Specialists

• Alimera – A Randomized, Masked, Controlled Study of Intravitreal ILUVIEN→ Implant as Baseline Therapy in Patients with Early Diabetic Macular Edema (DME) (NEW DAY / 01-20-005)

• EyePoint – A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD (DAVIO / EYP-1901-201)

• EyePoint A Phase 2, Multicenter, Prospective, Double-masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), compared to Sham for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR) (PAVIA / EYP-1901-204)

• Genentech – A Multicenter, Open-Label Extension Study To Evaluate The Long-Term Safety And Tolerability Of Faricimab In Patients With Neovascular Age-Related Macular Degeneration (AVONELLE-X / GR42691)

• Genentech - A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator Controlled Study To Evaluate The Efficacy And Safety of Faricimab in Patients With Macular Edema Secondary To Central Retinal or Hemiretinal Vein Occlusion (COMINO / GR41986)

• Genentech - A Phase III, Multicenter, Randomized, Visual Assessor Masked, Active Comparator Study Of The Efficacy, Safety, And Pharmacokinetics Of The Port Delivery System With Ranibizumab In Patients With Diabetic Macular Edema (PAGODA / GR40550)

• Genentech - A Phase III, Multicenter, Randomized Study Of The Efficacy, Safety, And Pharmacokinetics Of The Port Delivery System With Ranibizumab In Patients With Diabetic Retinopathy (PAVILION / GR41675)

• Genentech -A Multicenter, Open-Label Extension Study To Evaluate The Long-Term Safety And Tolerability Of The Ranibizumab Port Delivery System In Patients With Neovascular Age-Related Macular Degeneration Who Have Completed A Genentech-Sponsored Study (PORTAL / GR40459)

• Kodiak - A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO) (BEACON / KS301P103)

• Kodiak - Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301Compared with Intravitreal Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD) (DAYLIGHT / KS301P107)

• Kodiak - A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME) (GLEAM / KS301P104)

• Kodiak - A Prospective, Randomized, Double-masked, Sham-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants with Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR) (GLOW / KS301P106)

• Gyroscope -A Phase II, Open-Label, Outcomes-Assessor Masked, Multicenter, Randomized, Controlled Study To Evaluate The Safety And EFFICACY OF TWO DOSES OF GT005 ADMINISTERED AS A SINGLE SUBRETINAL INJECTION IN SUBJECTS WITH GEOGRAPHIC ATROPHY SECONDARY TO DRY AGE-RELATED MACULAR DEGENERATION (HORIZON / GT005-03)

• Hengenix – A Phase III, Global, Randomized, Double-Masked Active Controlled Study to Compare the Efficacy and Safety of HLX04-O Administered by Intravitreal Injection with Ranibizumab in subjects with Wet Age-Related Macular Degeneration (wAMD) (HENLIUS /HLX04-O-wAMD)

• OcuTerra - A Phase 2 Randomized, Double-Masked, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of OTT166 Ophthalmic Solution in the Treatment of Diabetic Retinopathy (DR) (DREAM / OTT166-201)

• Opthea - A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age related Macular Degeneration (Protocol Coast / OPT-302-1005)

• Regeneron - A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients with Diabetic Macular Edema (PHOTON / VGFTe-HD-DME-1934)

• RegenX - A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (ASCENT / RGX-314-3101)

• RegenX - A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (ATMOSPHERE / RGX-314-2104)